LY3857210 for Osteoarthritis, Knee

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Osteoarthritis, Knee+2 More
LY3852710 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3857210 in participants with Osteoarthritic Pain

Eligible Conditions
  • Osteoarthritis, Knee

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 13 Secondary · Reporting Duration: Baseline to Week 8

Baseline Through Week 8
Pharmaceutical Preparations
Baseline to Week 8
Change from Baseline for Emotional Functioning as measured by the EuroQol-5D-5-Level Questionnaire (EQ-5D-5L)
Pain
Percentage of Participants with Reduction from Baseline Greater Than or Equal to 30%, 50%, and 70% on the Physical Functioning Measures as described in the DSA
Pain
Pain
Pain
Pain
Week 8
Pain
Change from Baseline for Disease State Assessment (DSA)
Change from Baseline for Overall improvement as Measured by Patient's Global Impression of Change
Pain
Change from Baseline for on the Sleep Scale from the Medical Outcomes Study (MOS) Sleep Scale
Pain

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

Trial Design

2 Treatment Groups

LY3857210
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

125 Total Participants · 2 Treatment Groups

Primary Treatment: LY3857210 · Has Placebo Group · Phase 2

LY3857210
Drug
Experimental Group · 1 Intervention: LY3852710 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 8

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,455 Previous Clinical Trials
3,120,661 Total Patients Enrolled
14 Trials studying Osteoarthritis, Knee
3,506 Patients Enrolled for Osteoarthritis, Knee
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,252 Previous Clinical Trials
367,489 Total Patients Enrolled
8 Trials studying Osteoarthritis, Knee
1,741 Patients Enrolled for Osteoarthritis, Knee

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a VAS pain value of 40 or less during screening.
You have a body mass index <40 kg/m² (inclusive).
You are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
You are willing to discontinue all medications taken for chronic pain conditions for the duration of the study.
You have pain in your knee.
You have an x-ray supporting diagnosis of osteoarthritis of the knee with a Kellgren-Lawrence grade 2 to 4 radiographic classification of the index knee.
Men, or women, are able to abide by reproductive and contraceptive requirements.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: November 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.